Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
4 competitors in Kidney Transplantation
View Full LandscapeNo patent data available. Pre-approval drugs may not have Orange Book listings.
Simulect
Simulect is indicated for the prophylaxis of acute organ rejection in de-novo allogeneic renal transplantation in adult and paediatric patients (1-17 years). It is to be used concomitantly with ciclosporin for microemulsion- and corticosteroid-based immunosuppression, in patients with panel reactive antibodies less than 80%, or in a triple maintenance immunosuppressive regimen containing ciclosporin for microemulsion, corticosteroids and either azathioprine or mycophenolate mofetil.
View on EMA